Background: Pulmonary arterial hypertension (PAH) has been identified as a life threatening complication of connective tissue disease. However, the association between serum uric acid (UA) levels and long-term outcome in PAH with connective tissue disease has not been evaluated. We therefore assessed whether serum UA levels are related to the mortality of such patients.
PULMONARY arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance, leading to right-sided heart failure and premature death.
1) The Third World Symposium on Pulmonary Arterial Hypertension recently classified pulmonary hypertension (PH) that can present in an idiopathic form as idiopathic PAH. 1) This condition is also associated with various pathological states such as connective tissue disease, human immunodeficiency virus (HIV) infection, portal hypertension, congenital systemic-topulmonary shunts, and anorectic drug ingestion.
2) As a life-threatening complication of connective tissue disease, the development of PAH is a poor prognostic sign. Previous studies have suggested that PAH associated with scleroderma is more lethal than idiopathic PAH. [3] [4] [5] Furthermore, small, uncontrolled studies of mixed groups of patients with scleroderma, systemic lupus erythematosus, and mixed connective tissue disorder found that the prognosis of patients with PAH was very poor. [6] [7] [8] Elevated serum uric acid (UA) has recently been analyzed in patients with chronic heart disease, 9) cyanotic congenital heart disease, 10) and chronic obstructive lung disease. [11] [12] [13] Several studies have showed a close relationship between hyperuricemia and heart failure or other cardiovascular diseases. 14) Moreover, the serum uric acid concentration is closely correlated with the severity of symptoms and mortality in patients with idiopathic PAH 15) or Eisenmenger syndrome. 16) However, the association between serum UA levels and long-term outcome in PAH secondary to connective tissue disease has not been evaluated. The present study examines whether serum UA levels are related to the mortality of patients with PAH secondary to connective tissue disease.
METHODS

Patients:
The study population was comprised of 96 consecutive patients with connective tissue disease who were initially diagnosed with PH by echocardiography at our institution between January 1, 1995 and August 31, 2005. None of them had left-sided atrial, ventricular or valvular disease, thromboembolic disease, obstructive pulmonary disease, or congenital cardiac abnormalities. Three patients were excluded because of the absence of serum UA data, and 3 others were excluded because of renal failure (serum creatinine ≥ 2.0 mg/dL). The remaining 90 patients were divided into two groups according to the median serum UA level (UA = 4.7 mg/dL) that had been measured at the time of PH diagnosis. Echocardiography: All patients underwent conventional two-dimensional echocardiography (2DE) with a 3.5 mHz transducer. Right ventricular systolic pressure was estimated based on the modified Bernoulli equation and was considered to be equal to the systolic pulmonary artery pressure (sPAP) in the absence of right ventricular outflow obstruction: sPAP (mmHg) = Right Ventricular Systolic Pressure = Trans-tricuspid Gradient (4v 2 , v = peak velocity of tricuspid regurgitation, m/second) + Right Atrial Pressure (RAP).
17) The estimated RAP was 5 or 10 mmHg based on variations in the size of the inferior vena cava with inspiration as follows: complete collapse, RAP = 5 mmHg; no collapse, RAP = 10 mmHg. We defined PH as systolic pulmonary artery pressure (sPAP) equal to or greater than 40 mmHg. This value was selected based on the criteria estab-Vol 48 No 4 lished by the World Health Organization Symposium on Primary Pulmonary Hypertension (1998), which defines mild PH as a sPAP range of 40-50 mmHg. Blood sampling data: Medical records from the entire cohort revealed that serum uric acid, creatinine, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) had been measured in each patient in close temporal proximity to the echocardiographic study. When the clinical status or medication regimens changed between blood sampling and the echocardiographic study, the patient was excluded from the present study. Serum UA levels were determined using the uricase-peroxidase method.
18)
Patient follow-up: We analyzed clinical events and their causes from the date of the first PAH diagnosis until August 31, 2005 . Patient follow-up information was obtained from hospital charts recorded by a single cardiologist. The study outcomes were all causes of death and PAH-related death. We defined PAH-related death as due to events such as right-sided heart failure, respiratory failure, and sudden death. Statistical analysis: Continuous data are expressed as the mean ± SD. We used the chi-square test to compare baseline characteristics of patients with lower serum UA levels and those that were above the median value (UA = 4.7 mg/dL). Continuous variables were analyzed using Student's t test. Survival and eventfree survival rates were assessed by the Kaplan-Meier method, and survival curves between the two groups were compared using the log-rank test. We applied the Cox proportional hazard model to determine the independent relation- ship between late mortality and serum UA levels. A P value of < 0.05 was considered significant.
The variables were age, gender, presence of interstitial pneumonia, sPAP, ejection fraction, levels of serum CRP, ESR, and serum creatinine, as well as medication with beraprost, calcium channel blockers (CCB), anticoagulants, immunosuppressants, and antihyperuricemic drugs.
RESULTS
Patient characteristics:
The distribution of serum UA levels in each patient is shown in Figure 1 . Table I summarizes the baseline characteristics of the 90 patients. Of these, 46 (51.1%) and 44 (48.9%) patients were classified into the low (UA < 4.7 mg/dL) and high (UA ≥ 4.7 mg/dL) UA groups, respectively. The two groups showed no significant difference in terms of age, gender, presence of interstitial pneumonia, erythrocyte sedimentation rate, C-reactive protein levels, and systolic pulmonary artery pressure. The connective tissue diseases were also not significantly different in terms of the numbers of each type of disease when the patients had several conditions. There were significantly more patients who had a more severe New York Heart Association (NYHA) functional classification in the high UA group (P = 0.01). There was also no significant difference between the therapeutic agents used to treat PAH and those such as immunosuppressive drugs to treat connective tissue diseases. Serum creatinine levels tended to be higher in the high than in the low UA group, although the difference did not reach statistical significance (P = 0.06). 
Long-term outcome:
During the follow-up period (average, 24.2 months), a total of 27 patients died. Among these, 15 died of cardiopulmonary causes. Twelve of 15 patients died of progressive heart failure and respiratory failure, and 3 of 15 died suddenly, indicating a cardiopulmonary cause. Six patients died of infection (pneumonia, n = 5; pancreatitis, n = 1). Three patients died of bleeding (GI bleeding, n = 2; cerebral hemorrhage, n = 1) and 3 others died of other causes (malignancy, n = 2; hepatic failure, n = 1). All cause mortality was 30.2% lower in the low UA group (15.2% versus 45.4%, P = 0.002). Similarly, the PAH-related death rate was 20.7% lower in this group (6.5% versus 27.2%, P = 0.009) (Table II) . Kaplan-Meier analysis demonstrated a significantly lower all-cause rate of death in the low UA group (log-rank P < 0.01). The PAH-related mortality was significantly lower in the low (log-rank P < 0.01) than in the high UA group, and the rate was similar to that of all cause of mortality ( Figure 2 ). Table III presents the hazard ratio for the end-point of the elevation of serum UA levels. After adjusting the covariates, the prognostic significance of serum UA levels remained unchanged. The risk of all-cause death (HR = 1.88, 95%CI [1.24-2.84], P = 0.002) was significantly higher in the high UA group (Table III) . On the other hand, the risk of PAH-related death did not reach statistical significance.
DISCUSSION
Our registry data indicated that an elevated serum UA level at the time of PAH diagnosis was relevant to long-term mortality for patients with PAH secondary to connective tissue disease. We found that serum UA levels were related to long-term outcome in PAH secondary to connective tissue disease. Moreover, the results indicated that serum UA levels might be a useful prognostic predictor for PAH associated with connective tissue disease.
Several reports have demonstrated an association between serum UA levels and mortality due to idiopathic PAH. Nagaya, et al 15) found from a study of 102 consecutive patients that serum UA levels were significantly elevated in patients with idiopathic PAH as compared with controls and that they were independently related to mortality. Wensel, et al 19) also examined serum UA levels in 86 consecutive patients with idiopathic PAH between 1996 and 2001. In their study, serum UA levels were independently related to survival, but subsequent analysis of receiver operating characteristic curves did not demonstrate substantial predictive power. Voelkel, et al 20) demonstrated a positive correlation between pulmonary artery pressure and serum UA levels in a study of 92 patients with secondary pulmonary hypertension (connective tissue disease, n = 23). However, their study did not address the relationship between serum UA levels and prognosis.
The pathophysiological mechanisms leading to PAH secondary to connective tissue disease remain unknown. A number of studies have suggested that an immunological mechanism and inflammation might play a role in the pathogenesis of PAH with connective tissue disease. 21, 22) Elevated serum UA levels might reflect impaired oxidative metabolism by xanthine oxidase activity, since tissue hypoxia and cell death deplete adenosine triphosphate with degradation of adenosine nucleotides to compounds including UA. 23, 24) In addition to oxidative metabolism, an increase in serum UA concentrations is a marker of inflammatory cytokine activation and impaired vascular function in various cardiovascular diseases. 25, 26) Additionally, several recent studies have revealed that oxidative stress decreased with epoprostenol therapy in PAH patients. 27, 28) Because it is well known that epoprostenol has improved the outcome of PAH patients, 2, 6, 29) oxidative stress may be related to the prognosis of PAH.
Our results demonstrated that the number of patients with elevated UA levels was increased with increasing severity according to the NYHA functional classification. The NYHA functional classification is widely recognized as a marker of severity in PAH, and it was influenced by various hemodynamic data in PAH patients. 29, 30) Our retrospective analysis of the data did not show the biochemical and hemodynamic factors which affected the severity of the NYHA functional classification. We speculate that other reasons, which are independent of sPAP, may be related to the severity in PAH patients with connective tissue disease.
In addition to these mechanisms, the use of diuretics and renal impairment are considered to contribute to elevated serum UA levels. In the present study, medication with diuretics and serum creatinine levels did not significantly differ between the low and high UA groups, and multivariate analysis showed that elevated UA levels constituted a powerful independent predictor.
Analysis of the baseline characteristics of the patients showed that sPAP and serum UA levels did not correlate in this study. Nagaya, et al 15) have reported that serum UA levels correlated with cardiac output and total pulmonary resistance, but not with mean pulmonary arterial pressure. We did not demonstrate detailed hemodynamic data, which revealed the correlation with serum UA acid, because cardiac catheterization was not performed in this study. Further studies are needed to evaluate hemodynamic data accurately by various examinations in a larger population.
In our study population, about 36% of patients were complicated with interstitial pneumonia (IP). Complication of IP is a well known cause of death in patients with connective tissue disease. Hubbard, et al 31) studied a large population database and found that the prognosis for patients who had IP associated with connective tissue disease and for those with idiopathic pulmonary fibrosis was equally poor. On the other hand, Trad, et al 32) recently investigated the association between the severity of IP in systemic sclerosis diagnosed by high-resolution computed tomography and PH determined by echocardiography. Their multivariate analysis showed that age and PAH were the only independent predictors of death, and they concluded that PAH was, independently of IP, a major prognostic factor for survival. In our study, elevated serum UA levels comprised an independent predictor for prognosis when patients complicated with IP were excluded (HR = 2.36, 95%CI [1.29-4.28], P = 0.004). Thus, the results of the present study demonstrated a relationship between serum UA levels and a poor prognosis despite the influence of extant IP. Limitations: This study has several limitations. Firstly, it is an observational study of daily clinical practice with retrospective data collection. We could not therefore obtain data about biochemical markers, the 6-minute walk, cardiopulmonary exercise tests, and the influence of new treatment options (epoprostenol and bosentan therapy), the results of which are thought to be linked to the prognosis of all patients with PAH. 2, 6, 30, 33) Since whether serum UA levels are influenced by treating patients with PAH secondary to connective tissue disease remains unknown, further investigation is required to evaluate the association with serum UA levels and prognosis in a prospective study of a larger population. Secondly, despite strict quality control in a single institution, echocardiographic data generated by multiple operators might result in intraoperator variability. Moreover, echocardiographic findings are often inaccurately assessed, especially those of a tricuspid gradient. 34) These problems may explain some of the variation in our results. Conclusion: In this retrospective study of 90 consecutive PAH patients with connective tissue disease, we demonstrated that an elevated serum UA level at the time of PAH diagnosis was associated with a poor prognosis. Although the association with serum UA levels and prognosis for PAH secondary to connective tissue disease has not been adequately evaluated, the present results indicate that serum UA could be easy to collect and measure, and may provide a reproducible biological marker of prognosis.
